Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR

HOLON, ISRAEL, March 2, 2017 — Compugen Ltd. (NASDAQ: CGEN), a leading therapeutic discovery company, announced today that two abstracts, the first covering data of its lead pipeline product and another on its predictive discovery methodologies for novel immune checkpoints, will be presented as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, to take place April 1-5, 2017 in Washington, DC.

Summary results of COM701, Compugen’s lead antibody targeting PVRIG for cancer immunotherapy, will be highlighted in a poster presentation. Identified through the Company’s predictive discovery efforts, PVRIG is a novel immune checkpoint that operates as an inhibitory T cell regulator in the well-known TIGIT axis, suggesting that COM701 will offer both monotherapy and combination therapy opportunities:

**Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG**
Abstract 581, Sunday, Apr 2, 1:00 - 5:00 pm ET, poster presentation

Compugen’s computational target discovery methodologies for novel immune checkpoints will also be presented in a poster session, “**From Code to Cure™**.” The Company will present the computational method that led to the discovery of PVRIG, TIGIT, and additional novel immune checkpoints. Compugen’s discovery platform is based on the analysis of genomic sequences and structural genomic features that were identified by its computational systems and methodologies as typical characteristics of B7/CD28 immune checkpoint family members.

**From Code to Cure: Computational discovery of novel immune checkpoints**
Abstract 584, Sunday, Apr 2, 1:00 - 5:00 pm ET, poster presentation

Following the presentations, the posters will be made available for viewing on Compugen’s website at www.cgen.com.

**About Compugen**
Compugen is a leading therapeutic discovery company whose mission is to utilize its broadly applicable predictive discovery infrastructure to discover novel drug targets and develop first-in-class therapeutics. Our current pipeline consists of early and preclinical stage immuno-oncology programs based on novel drug targets discovered internally, primarily immune checkpoint and myeloid protein target candidates. These programs focus on the development of first-in-class cancer immunotherapy drugs with the potential to harness the immune system to provide treatment solutions in areas of unmet medical need in various cancer types and patient
populations, both as monotherapy and in combination with other drugs. In addition, our pipeline currently includes a preclinical stage fusion protein autoimmune product candidate. Compugen’s business model is based on selectively entering into collaborations for its novel target candidates and related drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, therapeutic monoclonal antibodies are discovered and developed against the Company’s novel drug target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” and “intends,” and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties, and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:
Susanna Chau
Director, Investor Relations and Corporate Communications
Compugen
Email: susannac@cgen.com
Tel: +1 (650) 263-7001